Canaccord Genuity Maintains Buy on Compass Therapeutics, Lowers Price Target to $7

Benzinga Newsdesk www.benzinga.com Negative 68.1%

Neg 68.1% Neu 0% Pos 0%

Canaccord Genuity analyst John Newman maintains Compass Therapeutics (NASDAQ:CMPX) with a Buy and lowers the price target from $13 to $7.